Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 3
2004 3
2005 6
2006 14
2007 13
2008 5
2009 11
2010 9
2011 4
2012 10
2013 12
2014 12
2015 5
2016 5
2017 4
2018 11
2019 10
2020 11
2021 15
2022 7
2023 6
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

162 results

Results by year

Filters applied: . Clear all
Page 1
Pre-B acute lymphoblastic leukemia presenting with NPM1 and FLT3 mutations.
Khan AA, James D, Andresen V, Atkey J, Bradbury R, Cargo C, Dillon R, Gjertsen BT, Goldstone AR, Leach R, Lock D, Narayanan M, Russell N, Verigou EA, Green S, Fielding AK, Falini B. Khan AA, et al. Among authors: gjertsen bt. Am J Hematol. 2024 Apr 3. doi: 10.1002/ajh.27301. Online ahead of print. Am J Hematol. 2024. PMID: 38567798 No abstract available.
Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
Flygt H, Söderlund S, Richter J, Saussele S, Koskenvesa P, Stenke L, Mustjoki S, Dimitrijevic A, Stentoft J, Majeed W, Roy L, Wolf D, Dreimane A, Gjertsen BT, Gedde-Dahl T, Ahlstrand E, Markevärn B, Hjorth-Hansen H, Janssen J, Olsson-Strömberg U. Flygt H, et al. Among authors: gjertsen bt. Leukemia. 2024 Apr;38(4):925. doi: 10.1038/s41375-024-02184-z. Leukemia. 2024. PMID: 38418611 Free PMC article. No abstract available.
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
Flygt H, Söderlund S, Richter J, Saussele S, Koskenvesa P, Stenke L, Mustjoki S, Dimitrijevic A, Stentoft J, Majeed W, Roy L, Wolf D, Dreimane A, Gjertsen BT, Gedde-Dahl T, Ahlstrand E, Markevärn B, Hjorth-Hansen H, Janssen J, Olsson-Strömberg U. Flygt H, et al. Among authors: gjertsen bt. Leukemia. 2024 Apr;38(4):781-787. doi: 10.1038/s41375-024-02145-6. Epub 2024 Jan 26. Leukemia. 2024. PMID: 38278960 Free PMC article.
Hever kvaliteten på behandling av kreft.
Helland Å, Steinskog ESS, Blix ES, Flobak Å, Brabrand S, Puco K, Niehusmann P, Meltzer S, Oppedal IA, Haug Å, Torkildsen CF, Randen U, Gilje B, Lønning PE, Gjertsen BT, Hovland R, Russnes HG, Fagereng GL, Smeland S, Tasken K. Helland Å, et al. Among authors: gjertsen bt. Tidsskr Nor Laegeforen. 2024 Jan 18;144(1). doi: 10.4045/tidsskr.23.0740. Print 2024 Jan 23. Tidsskr Nor Laegeforen. 2024. PMID: 38258713 Free article. Norwegian. No abstract available.
WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy.
Fløisand Y, Remberger M, Bigalke I, Josefsen D, Vålerhaugen H, Inderberg EM, Olaussen RW, Gjertsen BT, Goedkoop R, Geiger C, Prinz PU, Schnorfeil FM, Pinkernell K, Schendel DJ, Kvalheim G. Fløisand Y, et al. Among authors: gjertsen bt. Leukemia. 2023 Sep;37(9):1842-1849. doi: 10.1038/s41375-023-01980-3. Epub 2023 Jul 28. Leukemia. 2023. PMID: 37507426
Author Correction: Early response evaluation by single cell signaling profiling in acute myeloid leukemia.
Tislevoll BS, Hellesøy M, Fagerholt OHE, Gullaksen SE, Srivastava A, Birkeland E, Kleftogiannis D, Ayuda-Durán P, Piechaczyk L, Tadele DS, Skavland J, Baliakas P, Hovland R, Andresen V, Seternes OM, Tvedt THA, Aghaeepour N, Gavasso S, Porkka K, Jonassen I, Fløisand Y, Enserink J, Blaser N, Gjertsen BT. Tislevoll BS, et al. Among authors: gjertsen bt. Nat Commun. 2023 Mar 30;14(1):1767. doi: 10.1038/s41467-023-37488-8. Nat Commun. 2023. PMID: 36997540 Free PMC article. No abstract available.
A phase I prospective, non-randomized trial of autologous dendritic cell-based cryoimmunotherapy in patients with metastatic castration-resistant prostate cancer.
Thomsen LCV, Honoré A, Reisæter LAR, Almås B, Børretzen A, Helle SI, Førde K, Kristoffersen EK, Kaada SH, Melve GK, Haslerud TM, Biermann M, Bigalke I, Kvalheim G, Azeem W, Olsen JR, Gabriel B, Knappskog S, Halvorsen OJ, Akslen LA, Bahn D, Pantel K, Riethdorf S, Ragde H, Gjertsen BT, Øyan AM, Kalland KH, Beisland C. Thomsen LCV, et al. Among authors: gjertsen bt. Cancer Immunol Immunother. 2023 Jul;72(7):2357-2373. doi: 10.1007/s00262-023-03421-7. Epub 2023 Mar 20. Cancer Immunol Immunother. 2023. PMID: 36939854 Free PMC article. Clinical Trial.
Early response evaluation by single cell signaling profiling in acute myeloid leukemia.
Tislevoll BS, Hellesøy M, Fagerholt OHE, Gullaksen SE, Srivastava A, Birkeland E, Kleftogiannis D, Ayuda-Durán P, Piechaczyk L, Tadele DS, Skavland J, Baliakas P, Hovland R, Andresen V, Seternes OM, Tvedt THA, Aghaeepour N, Gavasso S, Porkka K, Jonassen I, Fløisand Y, Enserink J, Blaser N, Gjertsen BT. Tislevoll BS, et al. Among authors: gjertsen bt. Nat Commun. 2023 Jan 7;14(1):115. doi: 10.1038/s41467-022-35624-4. Nat Commun. 2023. PMID: 36611026 Free PMC article.
162 results